Cargando…

Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database

BACKGROUND: Prostacyclins play an important role in the management of pulmonary arterial hypertension (PAH). Intravenous prostacyclin was the first disease-specific treatment for patients with PAH. Subcutaneous and nonparenteral (oral or inhaled) formulations have subsequently become available. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, Charles D., Pruett, Janis A., Lickert, Cassandra A., Berger, Ariel, Murphy, Brian, Drake, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397685/ https://www.ncbi.nlm.nih.gov/pubmed/29406840 http://dx.doi.org/10.18553/jmcp.2017.17228

Ejemplares similares

Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis
por: McConnell, John W., et al.
Publicado: (2020)

Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy
por: Ruiz, George, et al.
Publicado: (2018)

Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension
por: Studer, Sean, et al.
Publicado: (2019)

Role of prostacyclin in pulmonary hypertension
por: Mitchell, Jane A., et al.
Publicado: (2014)

Use of prostacyclin in pulmonary hypertension
por: Vicente, R, et al.
Publicado: (1998)

Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database
por: Berger, Ariel, et al.
Publicado: (2014)

Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database
por: Studer, Sean, et al.
Publicado: (2018)

Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2018)

Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
por: Lang, Irene M., et al.
Publicado: (2015)

Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs
por: Louis, Lam, et al.
Publicado: (2012)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Treatment Patterns in Patients with Uterine Fibroids With and Without a Diagnosis of Heavy Menstrual Bleeding: Results from a Large U.S. Claims Database
por: McKain, Laura, et al.
Publicado: (2023)

Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension
por: Kingman, Martha, et al.
Publicado: (2017)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways
por: Mandras, Stacy, et al.
Publicado: (2021)

Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis
por: Hart, Stephen A., et al.
Publicado: (2018)

Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
por: Wang, Pengwei, et al.
Publicado: (2022)

New Tricks for an Old Drug: Prostacyclins and Right Ventricular Contractility in Pulmonary Arterial Hypertension
por: Wertheim, Bradley M.
Publicado: (2022)

Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis
por: Zhang, Huijun, et al.
Publicado: (2016)

Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
por: Picken, Christina, et al.
Publicado: (2019)

Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations
por: Sargent, Therese, et al.
Publicado: (2020)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
por: Abu‐Rmaileh, Muhammad, et al.
Publicado: (2023)

Describing the Patient Journey of Women with Claims for Uterine Fibroids and Heavy Menstrual Bleeding Using a Commercial Database (2011–2020)
por: Agarwal, Sanjay K, et al.
Publicado: (2023)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
por: Idrees, Majdy, et al.
Publicado: (2015)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension
por: Vanderpool, Rebecca R., et al.
Publicado: (2022)

Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension
por: Davies, Evan W, et al.
Publicado: (2018)

The pulmonary and haematological toxicity of inhaled aerosolised prostacyclin
por: van Heerden, PV, et al.
Publicado: (1997)

Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors
por: Frantz, Robert P., et al.
Publicado: (2020)

The Acute Effects of Prostacyclin on Right Ventricular Contractility and Pulmonary Artery Coupling
por: Vanderpool, Rebecca R., et al.
Publicado: (2023)

Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension
por: Hopper, Rachel K., et al.
Publicado: (2018)

Prostacyclin: An Inflammatory Paradox
por: Stitham, Jeremiah, et al.
Publicado: (2011)

Paracrine Effects of Bone Marrow–Derived Endothelial Progenitor Cells: Cyclooxygenase-2/Prostacyclin Pathway in Pulmonary Arterial Hypertension
por: Jiang, Dong-Mei, et al.
Publicado: (2013)

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost
por: Channick, Richard N., et al.
Publicado: (2013)

Intratracheal Administration of Prostacyclin Analogue–incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension
por: Akagi, Satoshi, et al.
Publicado: (2016)

An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis
por: Ainscough, Alexander J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9kvousjnpvsii2pcp3kp5cqgps